Therapeutic agent for malignant mesothelioma and immunostimulant
US8658612B2 · kind B2 · utility
3Cited by
1References
3Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 30, 2009 |
| Grant date | Feb 25, 2014 |
| Priority date | — |
| Expiry date | Jul 30, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/022
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for potentiating the antitumor immunity in an animal by administering REIC/Dkk-3, or a therapeutic agent for malignant mesothelioma containing REIC/Dkk-3, or a vector containing the DNA as an active ingredient; wherein the DNA consists of the nucleotide sequence shown in SEQ ID NO: 1; or (b) a DNA hybridizing under stringent conditions to the DNA consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1 and encoding a protein having apoptosis-inducing activity and interleukin (IL-7) production-accelerating activity in cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.